NFE2L2 and urinary bladder cancer: Similarly, meta-analysis for NSCLC, Bladder cancer and Melanoma revealed no significant association of NFE2L2 MU with OS (HR: 1.20, 95% CI 0.78 − 1.85; 1.65, 95% CI 0.78 − 3.47; 0.68, 95% CI 0.16 − 2.83; Fig. 5F and Additional file 1: Fig. S5A).